UBN1 and pneumococcal pneumonia: The results of our study, together with characteristics of VT, such as receptor specificity, chemical stability, and low production costs [28], suggest that VT may possess great potential as a novel therapeutic agent for reduction of permeability in pneumococcal pneumonia-induced lung injury.